This study sought to determine the frequency and factors influencing Impulsive Control Disorders (ICDs) in prolactinoma patients undergoing treatment with dopamine agonists.
Methods
A cross-sectional study was conducted involving a convenience sample of 170 patients diagnosed with prolactinoma and receiving dopamine agonist therapy for at least 6 months. Participants were recruited from a single center.
Results
At least one self-reported ICD symptom was present in 23.5% of patients. The most prevalent ICD symptoms were binge eating (17.7%), hypersexuality (14.7%), and compulsive shopping (11.8%). Correlates of ICD symptoms were male gender, macroprolactinoma, elevated prolactin levels, and a previous mental disease history. The likelihood of ICDs increased with the cumulative dose of dopamine agonist medication and the length of treatment. Moreover, individuals with moderate to severe anxiety and depression had a greater risk for ICDs compared to those without the former symptoms.
Conclusions
Clinicians should prioritize attention to risk factors during initial diagnosis and ongoing treatment of patients with prolactinoma that may elevate the risk of CDs.
CiccarelliADalyAFBeckersA. The epidemiology of prolactinomas. Pituitary. 2005;8(1):3-6.
2.
MelmedSCasanuevaFFHoffmanAR, et al.Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288.
GillamMPMolitchMELombardiGColaoA. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27(5):485-534.
5.
ValassiEKlibanskiABillerBM. Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab. 2010;95(3):1025-1033.
6.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders-Text Revision (DSM-IV TR). Washington, DC: American Psychiatric Association; 2000.
7.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Health Disorders-V (DSM-V). Washington, DC: American Psychiatric Association; 2013.
8.
BastiaensJDorfmanBJChristosPJNirenbergMJ. Prospective cohort study of impulse control disorders in Parkinson’s disease. Mov Disord. 2013;28(3):327.
9.
Grall-BronnecMVictorri-VigneauCDonnioY, et al.Dopamine agonists and impulse control disorders: a complex association. Drug Saf. 2018;41(1):19-75.
10.
MoldeHMoussaviYKopperudSTErgaAHHansenALPallesenS. Impulse-control disorders in Parkinson’s disease: a meta-analysis and review of case-control studies. Front Neurol. 2018;9:330.
11.
NoronhaSStokesVKaravitakiNGrossmanA. Treating prolactinomas with dopamine agonists: always worth the gamble?Endocrine. 2016;51(2):205-210.
12.
DavieM. Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. J Neuropsychiatry Clin Neurosci. 2007;19(4):473.
13.
FalhammarHYarkerJY. Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med J Aust. 2009;190(2):97.
14.
GuptaAZimmermanRS. Hypersexuality in cabergoline-treated prolactinoma. Program of the 93rd Annual Meeting of the Endocrine Society. Boston, MA; 2011:P3-312.
15.
NannengaMRTebbenPJNippoldtTB. Development of impulse control disorders in patients with dopamine agonist treated prolactinomas: a case series. Program of the 93rd Annual Meeting of the Endocrine Society. Boston, MA; 2011.
16.
AlmanzarSZapata-VegaMIRayaJA. Dopamine agonist-induced impulse control disorders in a patient with prolactinoma. Psychosomatics. 2013;54(4):387-391.
17.
ThondamSKAlusiSO’DriscollKGilkesCECuthbertsonDJDaousiC. Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma. Clin Neuropharmacol. 2013;36(5):170-172.
18.
De SousaSMChapmanIMFalhammarHTorpyDJ. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists. Endocrine. 2017;55(2):618-624.
19.
BulwerCConnRShankarA, et al.Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma. Clin Endocrinol. 2017;86(6):862-864.
20.
GiladiNWeitzmanNSchreiberSShabtaiHPeretzC. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson’s disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol. 2007;21(5):501-506.
21.
Perez-LloretSReyMVFabreN, et al.Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with parkinson disease. Clin Neuropharmacol. 2012;35(6):261-265.
22.
SarathchandranPSomanSSarmaGKrishnanSKishoreA. Impulse control disorders and related behaviors in Indian patients with Parkinson’s disease. Mov Disord. 2013;28(13):1901-1902.
23.
Rodríguez-ViolanteMGonzález-LatapiPCervantes-ArriagaACamacho-OrdoñezAWeintraubD. Impulse control and related disorders in Mexican Parkinson’s disease patients. Parkinsonism Relat Disorders. 2014;20(8):907-910.
24.
WeintraubDKoesterJPotenzaMN, et al.Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589-595.
25.
MartinkovaJTrejbalovaLSasikovaMBenetinJValkovicP. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin Neuropharmacol. 2011;34(5):179-181.
26.
BancosINannengaMRBostwickJMSilberMHEricksonDNippoldtTB. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol. 2014;80(6):863-866.
27.
BarakeMEvinsAEStoeckelL, et al.Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary. 2014;17(2):150-156.
28.
CelikEOzkayaHMPoyrazBCSaglamTKadiogluP. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up. Endocrine. 2018;62(3):692-700.
29.
WeintraubDHoopsSSheaJA, et al.Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease. Mov Disord. 2009;24(10):1461-1467.
30.
PattonJHStanfordMSBarrattES. Factor structure of the Barratt impulsiveness scale. J Clin Psychol. 1995;51(6):768-774.
31.
GulecHTamamLGulecMY, et al.Psychometric properties of the Turkish version of the Barratt impulsiveness scale-11. Klin Psikofarmakol Bul. 2008;18(4):251-258.
32.
MooreTJGlenmullenJMattisonDR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med. 2014;174(12):1930-1933.
33.
GiraultJ-AGreengardP. The neurobiology of dopamine signaling. Arch Neurol. 2004;61(5):641-644.
AuyeungMTsoiTHTangWK, et al.Impulse control disorders in Chinese Parkinson’s disease patients: the effect of ergot-derived dopamine agonist. Parkinsonism Relat Disorders. 2011;17(8):635-637.
36.
VoonVSohrMLangAE, et al.Impulse control disorders in Parkinson disease: a multicenter case-control study. Ann Neurol. 2011;69(6):986-996.
37.
LeeJYKimJMKimJW, et al.Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disorders. 2010;16(3):202-207.
38.
ColaoAdi SarnoACappabiancaP, et al.Gender differences in the prevalence, clinical features, and response to cabergoline in hyperprolactinemia. Eur J Endocrinol. 2003;148(3):325-331.
39.
AthanasouliaAPSieversCIsingM, et al.Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. Eur J Endocrinol. 2012;167(3):327-335.
40.
MoellerFGBarrattESDoughertyDMSchmitzJMSwannAC. Psychiatric aspects of impulsivity. Am J Psychiatr. 2001;158(11):1783-1793.
41.
BancosINippoldtTBEricksonD. Hypersexuality in men with prolactinomas treated with dopamine agonists. Endocrine. 2017;56(3):456-457.
BaussartBVillaCJouinotA, et al.Pituitary surgery as an alternative to dopamine agonist treatment for microprolactinomas: a cohort study. Eur J Endocrinol. 2021;185:783-791. doi:10.1530/EJE-21-0293
44.
BeckersAAaltonenLADalyAFKarhuA. Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev. 2013;34:239-277. doi:10.1210/er.2012-1013
45.
BeumontPBruwerJPimstoneBVinikAUtianW. Brom-ergocryptine in the treatment of phenothiazine-induced galactorrhoea. Br J Psychiatry. 1975;126:285-288. doi:10.1192/bjp.126.3.285
CaputoCPriorDInderWJ. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. Lancet Diabetes Endocrinol. 2015;3:906-913. doi:10.1016/S2213-8587(14)70212-8
48.
CasanuevaFFMolitchMESchlechteJA, et al.Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol. 2006;65:265-273. doi:10.1111/j.1365-2265.2006.02562.x
49.
CasanuevaFFBarkanALBuchfelderM, et al.Pituitary Society, Expert Group on Pituitary Tumors. Criteria for the definition of pituitary tumor centers of excellence (PTCOE): a pituitary society statement. Pituitary. 2017;20:489-498. doi:10.1007/s11102-017-0838-2
50.
CavallaroRCocchiFAngeloneSMLattuadaESmeraldiE. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry. 2004;65:187-190. doi:10.4088/jcp.v65n0207. In this issue.
